Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis.

ABSTRACT:

Introduction

The global pandemic of coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It seems that there is an association between blood cancer and an increased risk of severe COVID-19. This study aimed to review the literature reporting the COVID-19 outcomes in patients with hematological malignancies.

Material and methods

In this systematic review and meta-analysis, Pubmed, Embase, and Web of Science databases were searched using the following keywords: COVID-19, SARS-CoV-2, blood cancer, myeloma, lymphoma, and leukemia. All the published articles in English from January 1, 2019, until March 10, 2021 were collected and evaluated.

Results

In total, 53 studies with 2395 patients were included based on i

SUBMITTER: Naimi A 

PROVIDER: S-EPMC9102765 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature